Biodistribution of 177lu-octreotate and 111in- minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 174-181

  Dalmo, Johanna ^a   Rudqvist, Nils ^a   Spetz, Johan ^a   Laverman, Peter ^b   Nilsson, Ola ^a   Ahlman, Håkan ^a   Forssell Aronsson, Eva ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

177lu octreotate; Biodistribution; Cck2 receptor; Medullary thyroid carcinoma; Somatostatin receptor

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; GASTRIN DERIVATIVE; GASTRIN RECEPTOR; INDIUM MINIGASTRIN IN 111; LUTETIUM OCTREOTATE LU 177; MINIGASTRIN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 177LU OCTREOTATE; 177LU-OCTREOTATE; DRUG DERIVATIVE; GASTRIN; INDIUM; OCTREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MEAN ABSORBED DOSE; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RADIOISOTOPE DECAY; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; NUDE MOUSE; SCINTISCANNING; THYROID TUMOR; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GASTRINS; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; OCTREOTIDE; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84855275225     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1494     Document Type: Article

References (51)

1. Kwekkeboom DJ, Kam BL, van Essen M, et al: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17: R53-P73, 2010.
2. Kolby L, Bernhardt P, Ahlman H, et al: A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 158: 745-755, 2001. (Pubitemid 32158636)
3. Nilsson O, Kolby L, Bernhardt P, Forssell-Aronsson E, Johanson V and Ahlman H: GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors. Ann N Y Acad Sci 1014: 275-279, 2004. (Pubitemid 38594816)
4. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T and Eden PA: Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15: 1229-1236, 1994. (Pubitemid 24337076)
5. Hashemi SH, Benjegard SA, Ahlman H, et al: 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours. Br J Surg 90: 549-554, 2003.
6. Evers BM, Hurlbut SC, Tyring SK, Townsend CM Jr, Uchida T and Thompson JC: Novel therapy for the treatment of human carcinoid. Ann Surg 213: 411-416, 1991.
7. Evers BM, Townsend CM Jr, Upp JR, et al: Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 101: 303-311, 1991.
8. Pfragner R, Wirnsberger G, Niederle B, et al: Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I). Int J Oncol 8: 513-520, 1996.
9. Modlin IM, Kidd M, Pfragner R, Eick GN and Champaneria MC: The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 91: 2340-2348, 2006. (Pubitemid 43855026)
10. Leong SS, Horoszewicz HJ, Friedman M, et al: A new cell-line for studies on human thyroid medullary carcinoma. Proc Am Assoc Cancer Res 22: 49-49, 1981.
11. Olszewska-Pazdrak B, Townsend CM Jr and Hellmich MR: Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant. J Biol Chem 279: 40400-40404, 2004. (Pubitemid 39287628)
12. Aloj L, Caraco C, Panico M, et al: In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med: 45: 485-494, 2004. (Pubitemid 47618625)
13. Aloj L, Aurilio M, Rinaldi V, et al: Comparison of the binding and internalization properties of 12 DOTA-coupled and (111)In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging 38: 1417-1425, 2011.
14. Bernhardt P, Kolby L, Johanson V, et al: Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor. Nucl Med Biol 28: 67-73, 2001. (Pubitemid 32155966)
15. Bernhardt P, Kolby L, Johanson V, Nilsson O, Ahlman H and Forssell-Aronsson E: Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol 30: 253-260, 2003. (Pubitemid 36556240)
16. Bernhardt P, Oddstig J, Kolby L, Nilsson O, Ahlman H and Forssell-Aronsson E: Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice. Cancer Biother Radiopharm 22: 644-653, 2007. (Pubitemid 350059001)
17. Kolby L, Bernhardt P, Johanson V, et al: Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 93: 1144-1151, 2005. (Pubitemid 41670699)
18. Schmitt A, Bernhardt P, Nilsson O, et al: Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm 18: 593-599, 2003. (Pubitemid 37082380)
19. Schmitt A, Bernhardt P, Nilsson O, et al: Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med 45: 1542-1548, 2004. (Pubitemid 47618508)
20. Schmitt A: Experimental studies of 177Lu-DOTA0,Tyr3-octreotate for radionuclide therapy of small cell lung cancer. Licentiate Thesis Department of Radiation Physics, Göteborg University, Göteborg. 2005.
21. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L and Forssell-Aronsson E: Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm 20: 231-236, 2005. (Pubitemid 40696108)
22. Taal BG, Hoefnagel C, Boot H, Valdes Olmos R and Rutgers M: Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 11: 1437-1443, 2000.
23. Kolby L, Bernhardt P, Levin-Jakobsen AM, et al: Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89: 1383-1388, 2003. (Pubitemid 37368903)
24. Amiri-Mosavi A, Ahlman H, Tisell LE, et al: Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer. Eur J Surg 165: 628-631, 1999. (Pubitemid 29377080)
25. Reubi JC, Schaer JC and Waser B: Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57: 1377-1386, 1997. (Pubitemid 27152565)
26. Reubi JC and Waser B: Unexpected high incidence of cholecystokinin-B/ gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 67: 644-647, 1996. (Pubitemid 26300980)
27. Behe M and Behr TM: Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 66: 399-418, 2002.
28. Behr TM, Jenner N, Radetzky S, et al: Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25: 424-430, 1998. (Pubitemid 28211607)
29. Behr TM, Jenner N, Behe M, et al: Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40: 1029-1044, 1999. (Pubitemid 29269226)
30. Behe M, Kluge G, Becker W, Gotthardt M and Behr TM: Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 46: 1012-1015, 2005. (Pubitemid 43733517)
31. Laverman P, Joosten L, Eek A, et al: Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging 38: 1410-1416, 2011.
32. Laverman P, Roosenburg S, Gotthardt M, et al: Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 35: 386-392, 2008.
33. Froberg AC, de Jong M, Nock BA, et al: Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 36: 1265-1272, 2009.
34. Nock BA, Maina T, Behe M, et al: CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 46: 1727-1736, 2005. (Pubitemid 46211597)
35. Gotthardt M, Behe MP, Beuter D, et al: Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33: 1273-1279, 2006. (Pubitemid 44630781)
36. Logsdon CD, Moessner J, Williams JA and Goldfine ID: Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells. J Cell Biol 100: 1200-1208, 1985. (Pubitemid 15093473)
37. Longnecker DS, Lilja HS, French J, Kuhlmann E and Noll W: Transplantation of azaserine-induced carcinomas of pancreas in rats. Cancer Lett 7: 197-202, 1979. (Pubitemid 9252709)
38. Roebuck BD, Yager JD Jr and Longnecker DS: Dietary modulation of azaserine-induced pancreatic carcinogenesis in the rat. Cancer Res 41: 888-893, 1981. (Pubitemid 11136331)
39. Johanson V, Ahlman H, Bernhardt P, et al: A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 14: 433-444, 2007. (Pubitemid 47242641)
40. Bolch WE, Eckerman KF, Sgouros G and Thomas SR: MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med 50: 477-484, 2009.
41. Forssell-Aronsson EB, Nilsson O, Bejegard SA, et al: 111In-DTPA-D-Phe1- octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 41: 636-642, 2000.
42. Tisell LE, Ahlman H, Wangberg B, et al: Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 84: 543-547, 1997. (Pubitemid 27196303)
43. de Araujo EB, Caldeira Filho JS, Nagamati LT, et al: A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours. Appl Radiat Isot: 67: 227-233, 2009.
44. Reubi JC, Schar JC, Waser B, et al: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27: 273-282, 2000. (Pubitemid 30167697)
45. Bates CM, Kegg H and Grady S: Expression of somatostatin in the adult and developing mouse kidney. Kidney Int 66: 1785-1793, 2004. (Pubitemid 41094302)
46. Bates CM, Kegg H and Grady S: Expression of somatostatin receptors 1 and 2 in the adult mouse kidney. Regul Pept 119: 11-20, 2004. (Pubitemid 38482097)
47. Bates CM, Kegg H, Petrevski C and Grady S: Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. Kidney Int 63: 53-63, 2003. (Pubitemid 35463906)
48. Sward C, Bernhardt P, Johanson V, et al: Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm 23: 114-120, 2008. (Pubitemid 351304215)
49. Forssell-Aronsson E, Bernhardt P, Nilsson O, Tisell LE, Wangberg B and Ahlman H: Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol 43: 436-442, 2004. (Pubitemid 39037091)
50. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D and Watson SA: Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 48: 615-622, 2007. (Pubitemid 47571419)
51. Lewis JS, Wang M, Laforest R, et al: Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 94: 873-877, 2001. (Pubitemid 33032837)